sub:assertion {
d:DB00761 dv:ddi-interactor-in dr:DB00761_DB01036 .
d:DB01036 dv:ddi-interactor-in dr:DB00761_DB01036 .
dr:DB00761_DB01036 dct:identifier "drugbank_resource:DB00761_DB01036" ;
dct:title "DDI between Potassium Chloride and Tolterodine - The ulcerative effects of solid oral dosage forms of KCl may be enhanced by the anticholinergic, Tolterodine. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Potassium Chloride and Tolterodine - The ulcerative effects of solid oral dosage forms of KCl may be enhanced by the anticholinergic, Tolterodine. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations. [drugbank_resource:DB00761_DB01036]"@en .
}